Onconova Therapeutics, Inc. (ONTX): Price and Financial Metrics
GET POWR RATINGS... FREE!
ONTX POWR Grades
- Sentiment is the dimension where ONTX ranks best; there it ranks ahead of 98.75% of US stocks.
- ONTX's strongest trending metric is Sentiment; it's been moving up over the last 179 days.
- ONTX's current lowest rank is in the Momentum metric (where it is better than 4.64% of US stocks).
ONTX Stock Summary
- For ONTX, its debt to operating expenses ratio is greater than that reported by merely 0.5% of US equities we're observing.
- ONTX's price/sales ratio is 179.37; that's higher than the P/S ratio of 98.53% of US stocks.
- Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for ONTX comes in at -137.06% -- higher than that of only 2.58% of stocks in our set.
- Stocks with similar financial metrics, market capitalization, and price volatility to Onconova Therapeutics Inc are NAVB, AEIS, MYSZ, GEOS, and SCYX.
- ONTX's SEC filings can be seen here. And to visit Onconova Therapeutics Inc's official web site, go to www.onconova.com.
ONTX Valuation Summary
- ONTX's price/earnings ratio is -3.9; this is 110.68% lower than that of the median Healthcare stock.
- Over the past 99 months, ONTX's price/sales ratio has gone up 347.8.
- Over the past 99 months, ONTX's price/sales ratio has gone up 347.8.
Below are key valuation metrics over time for ONTX.
Stock | Date | P/S | P/B | P/E | EV/EBIT |
---|---|---|---|---|---|
ONTX | 2021-08-31 | 356.4 | 2.5 | -3.9 | -1.9 |
ONTX | 2021-08-30 | 347.9 | 2.5 | -3.8 | -1.8 |
ONTX | 2021-08-27 | 349.2 | 2.5 | -3.8 | -1.8 |
ONTX | 2021-08-26 | 351.3 | 2.5 | -3.8 | -1.8 |
ONTX | 2021-08-25 | 342.4 | 2.4 | -3.7 | -1.7 |
ONTX | 2021-08-24 | 335.6 | 2.4 | -3.7 | -1.6 |
ONTX Growth Metrics
- Its 2 year cash and equivalents growth rate is now at 327.26%.
- Its 3 year net income to common stockholders growth rate is now at -22.29%.
- Its year over year price growth rate is now at 70.98%.

The table below shows ONTX's growth in key financial areas (numbers in millions of US dollars).
Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
---|---|---|---|
2021-09-30 | 0.227 | -20.69 | -18.828 |
2021-06-30 | 0.236 | -22.186 | -21.616 |
2021-03-31 | 0.235 | -23.26 | -24.78 |
2020-12-31 | 0.231 | -23.075 | -25.157 |
2020-09-30 | 0.204 | -22.967 | -24.475 |
2020-06-30 | 0.201 | -21.165 | -22.829 |
ONTX's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- ONTX has a Quality Grade of D, ranking ahead of 8.68% of graded US stocks.
- ONTX's asset turnover comes in at 0.007 -- ranking 403rd of 682 Pharmaceutical Products stocks.
- IDRA, MYMD, and CAPR are the stocks whose asset turnover ratios are most correlated with ONTX.
The table below shows ONTX's key quality metrics over time.
Period | Asset Turnover | Gross Margin | ROIC |
---|---|---|---|
2021-06-30 | 0.007 | 1 | 2.820 |
2021-03-31 | 0.008 | 1 | 3.136 |
2020-12-31 | 0.009 | 1 | 3.246 |
2020-09-30 | 0.007 | 1 | 3.342 |
2020-06-30 | 0.009 | 1 | 3.259 |
2020-03-31 | 0.123 | 1 | 2.890 |
ONTX Price Target
For more insight on analysts targets of ONTX, see our ONTX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
Average Price Target | $0.30 | Average Broker Recommendation | 1.5 (Moderate Buy) |
ONTX Stock Price Chart Interactive Chart >
ONTX Price/Volume Stats
Current price | $1.15 | 52-week high | $8.00 |
Prev. close | $1.12 | 52-week low | $1.00 |
Day low | $1.11 | Volume | 51,600 |
Day high | $1.17 | Avg. volume | 154,600 |
50-day MA | $1.48 | Dividend yield | N/A |
200-day MA | $2.71 | Market Cap | 24.03M |
Onconova Therapeutics, Inc. (ONTX) Company Bio
Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer.
Latest ONTX News From Around the Web
Below are the latest news stories about Onconova Therapeutics Inc that investors may wish to consider to help them evaluate ONTX as an investment opportunity.
Onconova Therapeutics (ONTX) Investor Presentation IP - SlideshowNo summary available. |
Onconova Therapeutics to Present at the Guggenheim Oncology ConferenceNEWTOWN, Pa., Feb. 02, 2022 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that the Company will be participating in the Guggenheim Oncology Conference taking place virtually February 9, 2022, through February 11, 2022. Steven Fruchtman, M.D., President & CEO of Onconova, will participate in a fireside chat on February 10, 2022, at 8:30 a.m. E |
Onconova Therapeutics to Present at the H.C. Wainwright BIOCONNECT Virtual ConferenceNEWTOWN, Pa., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that the Company will be participating in the H.C. Wainwright BIOCONNECT Virtual Conference taking place January 10, 2022, through January 13, 2022. A corporate overview presented by Steven Fruchtman, M.D., President & CEO of Onconova, will be available on-demand beginn |
Onconova Therapeutics Appoints Adar Makovski Silverstein, Ph.D., as Director, Corporate DevelopmentNEWTOWN, Pa., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that Dr. Adar Makovski Silverstein has joined Onconova as Director, Corporate Development. “Adar’s deep scientific expertise in oncology and business development experience at leading biotechnology companies, most recently at Amgen, make her an excellent addition to our |
We're Not Very Worried About Onconova Therapeutics' (NASDAQ:ONTX) Cash Burn RateEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the... |
ONTX Price Returns
1-mo | -17.27% |
3-mo | -29.01% |
6-mo | -61.67% |
1-year | -82.81% |
3-year | -97.63% |
5-year | -99.73% |
YTD | -54.90% |
2021 | -63.50% |
2020 | 21.62% |
2019 | -81.85% |
2018 | -90.62% |
2017 | -33.92% |
Continue Researching ONTX
Want to see what other sources are saying about Onconova Therapeutics Inc's financials and stock price? Try the links below:Onconova Therapeutics Inc (ONTX) Stock Price | Nasdaq
Onconova Therapeutics Inc (ONTX) Stock Quote, History and News - Yahoo Finance
Onconova Therapeutics Inc (ONTX) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...